Physician profile
Michael A Malone
NPI 1659384576
$10,738.24
in general payments reported to CMS, 2019-2025
40 companies · $2,236 in 2025
The $2,236 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $1,068 · 2021: $1,880 · 2022: $1,977 · 2023: $1,630 · 2024: $1,332 · 2025: $2,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,284 · Travel and Lodging: $914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,283.79 |
| Travel and Lodging | $914.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,264.24 | 2019-2025 | Triclip, Aveir, Mitraclip |
| Amgen INC. | $1,048.68 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $869.99 | 2019-2025 | Cds - Mct/Cem Monitoring, Watchman Access System, Rotablator Rotational Atherectomy System Console Kit |
| Medtronic, INC. | $722.30 | 2021-2024 | Cobalt Dr Mri Surescan, Micra, Aurora Ev-Icd Mri Surescan |
| Astrazeneca Pharmaceuticals Lp | $715.08 | 2019-2024 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $681.31 | 2019-2025 | |
| Inari Medical, INC. | $540.22 | 2021-2022 | |
| Pfizer INC. | $501.25 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $363.17 | 2020-2024 | Xarelto |
| Shockwave Medical, INC | $334.65 | 2022-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Abiomed | $308.35 | 2023-2025 | Impella |
| Cvrx, INC. | $262.77 | 2024-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $247.88 | 2020-2024 | Lifevest |
| Amarin Pharma, INC. | $187.70 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $175.23 | 2021-2023 | Verquvo, Belsomra, Januvia |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $175.04 | 2019-2025 | |
| Biotronik INC. | $160.00 | 2024-2025 | Selectra, Amvia Edge, Biomonitor |
| Novo Nordisk INC | $155.38 | 2021-2025 | Wegovy, Ozempic |
| Astellas Pharma US INC | $148.50 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $133.00 | 2019-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $125.76 | 2019-2022 | |
| Esperion Therapeutics, INC. | $116.55 | 2020-2024 | Nexletol |
| Biosense Webster, INC. | $65.49 | 2022-2023 | Carto 3, Octaray Mapping Catheter |
| Edwards Lifesciences Corporation | $50.89 | 2020-2025 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.27 | 2023-2024 | Jardiance |
| Cardiovascular Systems INC. | $37.73 | 2022 | |
| Bard Peripheral Vascular, INC. | $33.88 | 2019 | |
| Elutia, INC. | $33.55 | 2021-2022 | |
| Cleerly, INC. | $29.08 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Medtronic Vascular, INC. | $28.07 | 2020 | |
| Acumed LLC | $24.67 | 2025 | Biobridge, Ribloc |
| Corcept Therapeutics | $23.41 | 2025 | Korlym |
| Impulse Dynamics (USA) INC. | $22.52 | 2024 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $21.61 | 2024 | |
| Inspire Medical Systems, INC. | $20.45 | 2025 | Inspire |
| Angiodynamics, INC. | $15.31 | 2025 | Angiovac |
| Kiniksa Pharmaceuticals, Ltd. | $15.17 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $13.80 | 2023 | Opsumit, Uptravi |
| Kowa Pharmaceuticals America, INC. | $12.85 | 2021 | |
| Philips North America LLC | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.